BerGenBio to present late-breaking abstract on Phase II trial of bemcentinib in combination with KEYTRUDA® in advanced NSCLC at SITC
· Combination of selective AXL inhibitor bemcentinib and KEYTRUDA® featured in late breaking abstract at leading IO conference SITC · Analysis comprises stage 1 (n=24) in PhII trial in 2L advanced NSCLC · Stage 2 open and enrollingBergen, Norway, 2 November 2018 - BerGenBio ASA (OSE:BGBIO) announces that the analysis of the first stage of its Phase II clinical trial with bemcentinib, a first-in-class selective oral AXL inhibitor, in combination with the anti-PD-1 therapy KEYTRUDA® (pembrolizumab) in patients with previously treated, advanced non-small cell lung cancer (NSCLC) has been